Skip to main content

Centene Corp

Exchange: NYSESector: HealthcareIndustry: Healthcare Plans

Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach with local teams to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace.

Did you know?

Earnings per share grew at a 20.1% CAGR.

Current Price

$53.34

-0.65%

GoodMoat Value

$1901.11

3464.1% undervalued
Profile
Valuation (TTM)
Market Cap$26.23B
P/E-4.07
EV$13.21B
P/B1.31
Shares Out491.77M
P/Sales0.13
Revenue$198.10B
EV/EBITDA

Centene Corp (CNC) Valuation

GoodMoat Analysis

Based on data as of March 26, 2026

The current price of $32.73 appears deeply undervalued compared to the GoodMoat target of $1,870.18, implying an extreme margin of safety. However, this analysis is based on a target price that is clearly erroneous and unrealistic, rendering the valuation metrics unusable. A value investor must disregard this target and perform a fundamental valuation from scratch.

Read full analysis
Applying the GoodMoat Valuation Assessment framework reveals a critical data anomaly. The provided GoodMoat Target of $1,870.18 is astronomically higher than the current price of $32.73, suggesting a margin of safety exceeding 98%. According to the framework's DCF bands, this would classify the stock as 'Deeply Undervalued.' However, this target is implausible for a company with a $16.1B market cap and negative earnings, indicating a severe error in the target price calculation. The standard P/E ratio of -2.4 is meaningless due to negative EPS and cannot be compared to a sector average. The more informative metric is the Free Cash Flow Yield of 26.9%, which is exceptionally high and suggests the market price is low relative to the cash the business generates. For a value investor, this situation is a clear red flag regarding the reliability of the provided valuation benchmark. The analysis cannot proceed using the given target. A proper assessment would require building a new DCF model based on reasonable assumptions for this managed care organization, focusing on normalized earnings power, the sustainability of its high FCF yield, and its debt level (Debt/Equity of 0.87). The current data suggests the stock may be cheap on a cash flow basis, but the extreme discrepancy with the target price invalidates any conclusion based on it. Analysis based on data as of 2024-05-15.

CNC Fair Value Estimate

$1901.113464.1% undervalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

CNC Valuation Metrics

FCF$4.32B
FCF Growth Rate33.80%
EPS Growth (CAGR)20.13%
WACC10.00%

CNC Valuation & Fair Value Analysis

Centene Corp (CNC) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Centene Corp is $1901.11. The current stock price is $53.34, suggesting the stock is 3464.1% undervalued.

The price-to-earnings (P/E) ratio is -4.07. Price-to-book ratio is 1.31. Price-to-sales ratio is 0.13. PEG ratio is -0.22.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Centene Corp's intrinsic value.